Bioasis Technologies (FRA:107) ROCE % : 0.00% (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bioasis Technologies's annualized ROCE % for the quarter that ended in Nov. 2022 was 0.00%.

Bioasis Technologies ROCE % Historical Data

The historical data trend for Bioasis Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies ROCE % Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

ROCE %

Get a 7-Day Free Trial

-1,260.11

-1,079.67

-1,259.09

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
ROCE %	Get a 7-Day Free Trial															-492.36	-	-	-	-

Bioasis Technologies ROCE % Calculation

Bioasis Technologies's annualized ROCE % for the fiscal year that ended in Feb. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Feb. 2022 )		(A: Feb. 2021 )		(A: Feb. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Feb. 2022 )		(A: Feb. 2021 )		(A: Feb. 2022 )
	=	-2.493	/	( ( (2.134 - 1.237)	+	(1.571 - 2.072) )	/ 2 )
	=	-2.493	/	( (0.897	+	-0.501)	/ 2 )
	=	-2.493	/	0.198
	=	-1,259.09 %

Bioasis Technologies's ROCE % of for the quarter that ended in Nov. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Nov. 2022 )		(Q: Aug. 2022 )		(Q: Nov. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Nov. 2022 )		(Q: Aug. 2022 )		(Q: Nov. 2022 )
	=	-2.256	/	( ( (1.775 - 2.624)	+	(1.285 - 2.627) )	/ 2 )
	=	-2.256	/	( ( -0.849	+	-1.342 )	/ 2 )
	=	-2.256	/	-1.0955
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Nov. 2022) EBIT data.

Bioasis Technologies (FRA:107) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bioasis Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (FRA:107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines